LRRC15 and neoplasm: Where target antigens are co-expressed by the stroma and tumor (e.g., LRRC15, FAP), prefer payload-delivery strategies if the expression is tumor-dominant, and avoid indiscriminate stromal depletion when the lineage is ambiguous.